Literature DB >> 26511074

Coagulation activation in sickle cell trait: an exploratory study.

Chirag Amin1, Soheir Adam1, Micah J Mooberry1, Abdullah Kutlar2, Ferdane Kutlar2, Denise Esserman3, Julia E Brittain4, Kenneth I Ataga1, Jen-Yea Chang1, Alisa S Wolberg5, Nigel S Key1,5.   

Abstract

Recent epidemiologic data suggest that sickle cell trait (HbAS; AS) is a risk factor for venous thromboembolism. We conducted an exploratory study of healthy subjects with AS under baseline conditions to determine whether a chronic basal hyperactivation of coagulation exists, and if so, what mechanism(s) contribute to this state. Eighteen healthy AS individuals were compared to 22 African-American controls with a normal haemoglobin profile (HbAA; AA) and 17 patients with sickle cell disease (HbSS; SS). Plasma thrombin-antithrombin complexes and D-dimer levels were elevated in AS relative to AA patients (P = 0·0385 and P = 0·017, respectively), and as expected, were much higher in SSversusAA (P < 0·0001 for both). Thrombin generation in platelet poor plasma was indistinguishable between AA and AS subjects, whereas a paradoxical decrease in endogenous thrombin potential was observed in SS (P ≤ 0·0001). Whole blood tissue factor was elevated in SS compared to AA (P = 0·005), but did not differ between AA and AS. Plasma microparticle tissue factor activity was non-significantly elevated in AS (P = 0·051), but was clearly elevated in SS patients (P = 0·004) when compared to AA controls. Further studies in larger cohorts of subjects with sickle cell trait are needed to confirm the results of this preliminary investigation.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  coagulation; sickle; thrombin; tissue factor; venous thrombosis

Mesh:

Substances:

Year:  2015        PMID: 26511074      PMCID: PMC4782194          DOI: 10.1111/bjh.13641

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  51 in total

1.  Is there an acute-phase response in steady-state sickle cell disease?

Authors:  A Singhal; J F Doherty; J G Raynes; K P McAdam; P W Thomas; B E Serjeant; G R Serjeant
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

2.  Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease.

Authors:  N S Key; A Slungaard; L Dandelet; S C Nelson; C Moertel; L A Styles; F A Kuypers; R R Bach
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

3.  Sickle cell trait and the risk of venous thromboembolism among blacks.

Authors:  Harland Austin; Nigel S Key; Jane M Benson; Cathy Lally; Nicole F Dowling; Carolyn Whitsett; W Craig Hooper
Journal:  Blood       Date:  2007-04-04       Impact factor: 22.113

4.  Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study.

Authors:  P L Lutsey; M Cushman; L M Steffen; D Green; R G Barr; D Herrington; P Ouyang; A R Folsom
Journal:  J Thromb Haemost       Date:  2006-09-26       Impact factor: 5.824

5.  Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease.

Authors:  Paul D Stein; Afzal Beemath; Frederick A Meyers; Elias Skaf; Ronald E Olson
Journal:  Am J Med       Date:  2006-10       Impact factor: 4.965

6.  Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition.

Authors:  R Luddington; T Baglin
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

Review 7.  Thrombin generation, a function test of the haemostatic-thrombotic system.

Authors:  H Coenraad Hemker; Raed Al Dieri; Erik De Smedt; Suzette Béguin
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

8.  The PO2 in venous valve pockets: its possible bearing on thrombogenesis.

Authors:  J D Hamer; P C Malone; I A Silver
Journal:  Br J Surg       Date:  1981-03       Impact factor: 6.939

Review 9.  Hypercoagulability in sickle cell disease: new approaches to an old problem.

Authors:  Kenneth I Ataga; Nigel S Key
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

Review 10.  Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.

Authors:  Kenneth I Ataga; Maria D Cappellini; Eliezer A Rachmilewitz
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

View more
  12 in total

1.  Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study.

Authors:  Melissa C Caughey; Vimal K Derebail; Nigel S Key; Alexander P Reiner; Rebecca F Gottesman; Abhijit V Kshirsagar; Gerardo Heiss
Journal:  Am J Hematol       Date:  2019-09-10       Impact factor: 10.047

Review 2.  Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations.

Authors:  Lindsay Fernández-Rhodes; Kristin L Young; Adam G Lilly; Laura M Raffield; Heather M Highland; Genevieve L Wojcik; Cary Agler; Shelly-Ann M Love; Samson Okello; Lauren E Petty; Mariaelisa Graff; Jennifer E Below; Kimon Divaris; Kari E North
Journal:  Circ Res       Date:  2020-06-04       Impact factor: 17.367

3.  Elevated D-dimer levels in African Americans with sickle cell trait.

Authors:  Rakhi P Naik; James G Wilson; Lynette Ekunwe; Stanford Mwasongwe; Qing Duan; Yun Li; Adolfo Correa; Alexander P Reiner
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

4.  Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.

Authors:  Camille Faes; Anton Ilich; Amandine Sotiaux; Erica M Sparkenbaugh; Michael W Henderson; Laura Buczek; Joan D Beckman; Patrick Ellsworth; Denis F Noubouossie; Lantarima Bhoopat; Mark Piegore; Céline Renoux; Wolfgang Bergmeier; Yara Park; Kenneth I Ataga; Brian Cooley; Alisa S Wolberg; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2019-04-05       Impact factor: 22.113

Review 5.  Anti-inflammatory cytokines in sickle cell disease.

Authors:  Adekunle E Alagbe; Igor F Domingos; Adekunle D Adekile; Maria H S L Blotta; Magnun N N Santos
Journal:  Mol Biol Rep       Date:  2022-01-09       Impact factor: 2.316

6.  Silent Infarcts, White Matter Integrity, and Oxygen Metabolic Stress in Young Adults With and Without Sickle Cell Trait.

Authors:  Yan Wang; Kristin P Guilliams; Melanie E Fields; Slim Fellah; Michael M Binkley; Martin Reis; Katie D Vo; Yasheng Chen; Chunwei Ying; Morey Blinder; Allison A King; Monica L Hulbert; Hongyu An; Jin-Moo Lee; Andria L Ford
Journal:  Stroke       Date:  2022-05-12       Impact factor: 10.170

Review 7.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

8.  Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review.

Authors:  Rakhi P Naik; Kim Smith-Whitley; Kathryn L Hassell; Nkeiruka I Umeh; Mariane de Montalembert; Puneet Sahota; Carlton Haywood; Jean Jenkins; Michele A Lloyd-Puryear; Clinton H Joiner; Vence L Bonham; Gregory J Kato
Journal:  Ann Intern Med       Date:  2018-10-30       Impact factor: 25.391

9.  Bilateral Pulmonary Embolism after a Short-Haul Flight in a Man with Multiple Risk Factors including Sickle Cell Trait.

Authors:  Kamille Abdool; Kanterpersad Ramcharan; Antonio J Reyes; Nadiene Lutchman; Adrian Alexander
Journal:  Case Rep Emerg Med       Date:  2017-03-29

10.  D-Dimer in African Americans: Whole Genome Sequence Analysis and Relationship to Cardiovascular Disease Risk in the Jackson Heart Study.

Authors:  Laura M Raffield; Neil A Zakai; Qing Duan; Cecelia Laurie; Joshua D Smith; Marguerite R Irvin; Margaret F Doyle; Rakhi P Naik; Ci Song; Ani W Manichaikul; Yongmei Liu; Peter Durda; Jerome I Rotter; Nancy S Jenny; Stephen S Rich; James G Wilson; Andrew D Johnson; Adolfo Correa; Yun Li; Deborah A Nickerson; Kenneth Rice; Ethan M Lange; Mary Cushman; Leslie A Lange; Alex P Reiner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-09-14       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.